跳至主要内容
临床试验/ISRCTN39911673
ISRCTN39911673已完成不适用

Improving the management of cachexia in patients with advanced lung cancer: does the introduction of beta-hydroxy beta-methylbutyrate / arginine / glutamine (HMB/ARG/GLN) supplementation maintain lean body mass and quality of life?

niversity of Birmingham (UK)0 个研究点目标入组 96 人开始时间: 2011年5月19日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
96

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Newly diagnosed small cell lung cancer (SCLC) or non small cell lung cancer (NSCLC)
  • 2. Able to take oral nutrition
  • 3. WHO performance status 0-2
  • 4. Life expectancy greater than 4 months

排除标准

  • 1. Patients suitable for radical treatment with curative intent
  • 2. Patients who have already commenced first line chemotherapy or radiotherapy
  • 3. Patients for whom the diagnosis of lung cancer was made more than 8 weeks before trial entry
  • 4. Known or suspected to be pregnant
  • 5. Patients with pacemaker or internal defibrillator in situ

研究者

发起方
niversity of Birmingham (UK)

相似试验